{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T10:23:02Z","timestamp":1787998982020,"version":"build-2784847793"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00393-024-01519-6","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T11:01:51Z","timestamp":1715166111000},"page":"762-765","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Empfehlungen zur Definition von Riesenzellarteriitis-Fast-Track-Kliniken","Recommendations for defining giant cell arteritis fast-track clinics"],"prefix":"10.1007","volume":"83","author":[{"given":"Wolfgang A.","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Czihal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gernert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Hellmich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Ohrndorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Riemekasten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentin S.","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Strunk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Venhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,8]]},"reference":[{"key":"1519_CR1","doi-asserted-by":"publisher","first-page":"e003379","DOI":"10.1136\/rmdopen-2023-003379","volume":"9","author":"P Bosch","year":"2023","unstructured":"Bosch\u00a0P, Bond\u00a0M, Dejaco\u00a0C et\u00a0al (2023) Imaging in diagnosis, monitoring and outcome prediction of large vessel vasculitis: a\u00a0systematic literature review and meta-analysis informing the 2023 update of the EULAR recommendations. RMD Open 9:e3379","journal-title":"RMD Open"},{"key":"1519_CR2","doi-asserted-by":"publisher","unstructured":"Dejaco C, Ramiro S, Bond M et\u00a0al (2023) EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update. Ann Rheum Dis Aug. https:\/\/doi.org\/10.1136\/ard-2023-224543","DOI":"10.1136\/ard-2023-224543"},{"key":"1519_CR3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/rheumatology\/kev289","volume":"55","author":"AP Diamantopoulos","year":"2016","unstructured":"Diamantopoulos\u00a0AP, Haugeberg\u00a0G, Lindland\u00a0A et\u00a0al (2016) The fast-track ultrasound clinic for early diagnosis of giant cell arteritis significantly reduces permanent visual impairment: towards a\u00a0more effective strategy to improve clinical outcome in giant cell arteritis? Rheumatology 55:66\u201370","journal-title":"Rheumatology"},{"key":"1519_CR4","doi-asserted-by":"publisher","unstructured":"Keller KK, Mukhtyar CB, Nielsen AW et\u00a0al (2023) Recommendations for early referral of individuals with suspected polymyalgia rheumatica: an initiative from the international giant cell arteritis and polymyalgia rheumatica study group. Ann Rheum Dis Dec. https:\/\/doi.org\/10.1136\/ard-2023-225134","DOI":"10.1136\/ard-2023-225134"},{"key":"1519_CR5","doi-asserted-by":"publisher","first-page":"589794","DOI":"10.3389\/fmed.2020.589794","volume":"7","author":"S Monti","year":"2020","unstructured":"Monti\u00a0S, Bartoletti\u00a0A, Bellis\u00a0E, Delvino\u00a0P et\u00a0al (2020) Fast-track ultrasound clinic for the diagnosis of giant cell arteritis changes the prognosis of the disease but not the risk of future relapse. Front Med 7:589794","journal-title":"Front Med"},{"issue":"2 Suppl 89","key":"1519_CR6","first-page":"S103","volume":"33","author":"P Patil","year":"2015","unstructured":"Patil\u00a0P, Williams\u00a0M, Maw\u00a0WW et\u00a0al (2015) Fast track pathway reduces sight loss in giant cell arteritis: results of a\u00a0longitudinal observational cohort study. Clin Exp Rheumatol 33(2 Suppl 89):S103\u2013S106","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl 2","key":"1519_CR7","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s00393-021-01080-6","volume":"80","author":"A Pfeil","year":"2021","unstructured":"Pfeil\u00a0A, Krusche\u00a0M, Vossen\u00a0D et\u00a0al (2021) Model curriculum of the German society for Rheumatology for advanced training in the discipline internal medicine and rheumatology. Z\u00a0Rheumatol 80(Suppl 2):64\u201367 (English version)","journal-title":"Z Rheumatol"},{"key":"1519_CR8","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.3899\/jrheum.171428","volume":"45","author":"VS Sch\u00e4fer","year":"2018","unstructured":"Sch\u00e4fer\u00a0VS, Chrysidis\u00a0S, Dejaco\u00a0C et\u00a0al (2018) Assessing vasculitis in giant cell arteritis by ultrasound: Results of OMERACT patient-based reliability exercises. J\u00a0Rheumatol 45:1289\u20131295","journal-title":"J Rheumatol"},{"issue":"Suppl 3","key":"1519_CR9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00393-020-00893-1","volume":"79","author":"JH Schirmer","year":"2020","unstructured":"Schirmer\u00a0JH, Aries\u00a0PM, Balzer\u00a0K et\u00a0al (2020) S2k Guideline: Management of large vessel vasculitides. Z\u00a0Rheumatol 79(Suppl 3):67\u201395","journal-title":"Z Rheumatol"},{"issue":"Suppl 2","key":"1519_CR10","doi-asserted-by":"publisher","first-page":"ii22","DOI":"10.1093\/rheumatology\/kex461","volume":"57","author":"WA Schmidt","year":"2018","unstructured":"Schmidt\u00a0WA (2018) Ultrasound in the diagnosis and management of giant cell arteritis. Rheumatology 57(Suppl 2):ii22\u2013ii31","journal-title":"Rheumatology"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01519-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-024-01519-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-024-01519-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T06:03:26Z","timestamp":1730354606000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-024-01519-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,8]]},"references-count":10,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1519"],"URL":"https:\/\/doi.org\/10.1007\/s00393-024-01519-6","relation":{"has-translation":[{"id-type":"doi","id":"10.1007\/s00393-024-01532-9","asserted-by":"subject"},{"id-type":"doi","id":"10.1007\/s00393-024-01532-9","asserted-by":"object"}]},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,8]]},"assertion":[{"value":"23 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Die Idee f\u00fcr die Erstellung dieser Empfehlung entstand in einem von der Firma Novartis Pharma GmbH initiierten Expertengremium, in dem 8\u00a0der 10\u00a0Autoren vertreten waren (alle au\u00dfer VSS und WH). Alle weiteren Aktivit\u00e4ten zur Erstellung der Empfehlungen erfolgten dann unabh\u00e4ngig von Novartis. W.A.\u00a0Schmidt: <i>Als Referent t\u00e4tig f\u00fcr<\/i> AbbVie, Amgen, Bristol-Myers Squibb, Chugai, GlaxoSmithKline, Johnson & Johnson, Medac, Novartis, Roche, UCB; <i>Beraterhonorare<\/i> f\u00fcr AbbVie, Amgen, Fresenius Kabi, GlaxoSmithKline, Novartis, Sanofi; <i>Forschungsgelder<\/i> als Principal Investigator f\u00fcr AbbVie, GlaxoSmithKline, Novartis, Sanofi; <i>Mitglied von Leitlinienkommissionen<\/i> der EULAR (Bildgebung bei rheumatoider Arthritis, Management der PMR [EULAR\/ACR], Durchf\u00fchrung von Ultraschall-Trainerkursen, Ultraschall-Synovitis-Scoring, Management von Gro\u00dfgef\u00e4\u00dfvaskulitiden, Bildgebung bei Gro\u00dfgef\u00e4\u00dfvaskulitis 2018 und 2023, Publikation von Ultraschallstudien, Bildgebung bei Kristallarthropathien); der British Society for Rheumatology (Diagnose und Therapie der RZA), der AWMF (Management der Gro\u00dfgef\u00e4\u00dfvaskulitis, Management der Gicht) und der International GCA\/PMR Study Group (Empfehlung zur \u00dcberweisung bei Verdacht auf PMR). M.\u00a0Czihal: <i>Als Referent t\u00e4tig<\/i> f\u00fcr Bayer, Bristol-Myers Squibb, Lilly, Leo Pharma, MSD Sharp & Dohme, Novartis, Roche, UCB; <i>Beraterhonorare<\/i> f\u00fcr Novartis, Roche. M.\u00a0Gernert: <i>Als Referent t\u00e4tig<\/i> f\u00fcr AbbVie, Lilly, Janssen, Novartis; <i>Beraterhonorare<\/i> f\u00fcr Amgen, AstraZeneca, Novartis, Takeda; <i>Kongresssponsoring<\/i> von AbbVie, Lilly, Hexal, Janssen, Pfizer, UCB. W.\u00a0Hartung: <i>Als Referent t\u00e4tig<\/i> f\u00fcr AbbVie, Amgen, Bristol-Myers Squibb, Chugai, Novartis; Alpinion; Canon HealthCare; <i>Mitglied des Vorstands<\/i> der Deutschen Gesellschaft f\u00fcr Ultraschall in der Medizin. B.\u00a0Hellmich: <i>Als Referent t\u00e4tig<\/i> f\u00fcr AbbVie, AstraZeneca, BMS, GSK, Janssen, Novartis, Orgentec, Pfizer, Roche, Vifor; <i>Beraterhonorare<\/i> f\u00fcr AbbVie, BMS, InflaRx, GSK, Novartis, Roche, Vifor; <i>Mitglied von Leitlinienkommissionen<\/i>: Der Autor war federf\u00fchrend bzw. koordinativ an der Erstellung der EULAR-Recommendations 2018 und der DGRh-Leitlinie zum Management der Gro\u00dfgef\u00e4\u00dfvaskulitiden beteiligt. S.\u00a0Ohrndorf: <i>Als Referentin t\u00e4tig f\u00fcr<\/i> AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb (BMS), Galapagos (Alfasigma), Janssen, Mylan, Novartis, UCB; <i>Beraterhonorare<\/i> f\u00fcr Amgen, Janssen, Novartis; <i>Forschungsgelder<\/i> als Principal Investigator f\u00fcr Novartis. G.\u00a0Riemekasten: <i>Beraterhonorare<\/i> von Novartis. V.S.\u00a0Sch\u00e4fer: <i>Als Referent t\u00e4tig<\/i> f\u00fcr AbbVie, Novartis, BMS, Chugai, Celgene, Medac, Sanofi, Lilly, Hexal, Pfizer, Janssen, Roche, Schire, Onkowissen, Royal College London, Boehringer Ingelheim, UCB Fresenius, Alexion; <i>Beraterhonorare<\/i> von Novartis, Chugai, AbbVie, Celgene, Sanofi, Lilly, Hexal, Pfizer, Amgen, BMS, Roche, Gilead, Medac, Boehringer Ingelheim, Alexion; <i>Forschungsgelder <\/i>von Novartis, Hexal, Lilly, Roche, Celgene, Universit\u00e4t Bonn, Boehringer Ingelheim, Butterfly IQ, MEDAC, Alexion, DGRH. J.\u00a0Strunk: <i>Referenten- und Beraterhonorare<\/i> von AbbVie, Amgen, Chugai, BMS, Boehringer, GSK, Galapagos, Janssen-Cilag, Medac, Novartis, Pfizer, Roche, Sanofi, UCB. N.\u00a0Venhoff: <i>Als Referent t\u00e4tig<\/i> f\u00fcr AbbVie, AstraZeneca, BMS, Boehringer Ingelheim, Chugai, Celgene, GSK, Novartis, Pfizer, Janssen, Roche, UCB, Vifor. <i>Beraterhonorare<\/i> von AbbVie, AstraZeneca, Boehringer Ingelheim, GSK, Novartis, Pfizer, Janssen, Roche, UCB, Vifor. <i>Forschungsgelder<\/i> von AbbVie, Medac, Novartis, Pfizer. <i>Mitglied von Leitlinienkommissionen<\/i>: AWMF-Leitlinie zum Management der Gro\u00dfgef\u00e4\u00dfvaskulitiden.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}